Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Hetlioz
Pharma
Vanda gets $466M takeout bid from Cycle Pharma
England-based rare disease drug maker Cycle Pharma revealed an $8-per-share offer for Vanda, representing a total buyout offer of $466 million.
Eric Sagonowsky
Jun 6, 2024 10:10am
Supreme Court rejects Vanda's Hetlioz patent revival appeal
Apr 22, 2024 3:49pm
15 years later, Vanda secures another FDA nod for Fanapt
Apr 3, 2024 11:04am
Vanda scores courtroom win over FDA in records case
Mar 29, 2023 3:15pm
Teva, Apotex prevail over Vanda in patent infringement case
Dec 14, 2022 2:11pm
OPDP ramp-up spawns new letter warning Vanda for omitted risks
Nov 1, 2018 10:59am
